Based on data derived from three phase I trials and ten phase II/III studies in adult patients with schizophrenia or bipolar disorder treated with cariprazine, CYP2D6 metabolizer status was not associated with changes in exposure levels for the active moiety or the two active metabolites (99). The gene discussed is CYP2D6; the disease is schizophrenia.